drugset / Trial / NCT04447547
Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
Unknown
20 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
Beijing Lu Daopei Hospital · collabHebei Yanda Ludaopei Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study of patients with relapsed or refractory non-Hodgkin's lymphoma. To evaluate the safety and efficacy of SL1904B in patients with relapsed or refractory non-Hodgkin's lymphoma.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2022-08-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SL1904B | Unknown | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarine | Unknown | — | — |